<DOC>
	<DOCNO>NCT00557245</DOCNO>
	<brief_summary>Randomized , blind , placebo-controlled trial demonstrate pre-exposure prophylaxis decrease HIV-1 acquisition among HIV-1 uninfected individual within HIV-1 discordant couple .</brief_summary>
	<brief_title>Pre-Exposure Prophylaxis Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples</brief_title>
	<detailed_description>HIV-1 uninfected individual within HIV-1 discordant partnership high-risk HIV-acquisition . The majority HIV-1 transmission adult Africa occur within stable , HIV-1 discordant couple . Pre-exposure chemoprophylaxis , HIV-1 uninfected individual high risk contract HIV-1 take antiretroviral medication maintain blood genital drug level sufficient prevent HIV-1 acquisition , propose potential HIV-1 prevention strategy . This study randomize , blind , placebo-controlled trial demonstrate pre-exposure prophylaxis decrease HIV-1 acquisition among HIV-1 uninfected individual within HIV-1 discordant couple . The HIV-1 uninfected partner randomize 1:1:1 ratio one three arm : daily Tenofovir Disoproxil Fumarate ( TDF ) , Emtricitabine/Tenofovir Disoproxil Fumarate ( FTC/TDF ) Placebo . Couples follow 36 month ; HIV uninfected partner attend monthly visit HIV infect partner quarterly visit . All participant receive comprehensive package HIV prevention service include individual couple counsel , free condom , male circumcision referral . Participants seroconverted follow-up stop study drug continue follow-up .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Inclusion Criteria HIV1 uninfected partner : Partner within HIV1 discordant heterosexual relationship One partner meet study eligibility HIV1 uninfected study participant partner meet study eligibility criterion HIV1 infect participant Plan remain relationship duration study period Adequate renal , hepatic &amp; hematologic function Negative Hepatitis B surface antigen test Willing able provide write informed consent &amp; locator information Exclusion Criteria HIV1 uninfected partner : Current pregnancy , plan become pregnant study period Currently breastfeed Concurrent enrollment another HIV1 vaccine prevention trial Receiving ongoing antiretroviral therapy Repeated positive urine dipstick test glycosuria proteinuria Active serious infection History pathological bone fracture relate trauma Inclusion Criteria HIV1 infect partner : Partner within HIV1 discordant heterosexual relationship One partner meet study eligibility HIV1 uninfected study participant partner meet study eligibility criterion HIV1 infect participant HIV1 infect base positive EIA No history clinical AIDSdefining diagnose Plan remain relationship duration study period Willing able provide write informed consent &amp; locator information Exclusion Criteria HIV1 infect partner : Current use antiretroviral therapy Concurrent enrollment another HIV1 treatment trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>HIV uninfected partner</keyword>
	<keyword>Double Blind</keyword>
	<keyword>Placebo</keyword>
	<keyword>Seroconversion</keyword>
	<keyword>TDF</keyword>
	<keyword>FTC TDF</keyword>
	<keyword>Safety</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>